Skip to main content

SABCS 2021 Wrap-Up

Updated Outcomes of Tucatinib versus Placebo Added to Trastuzumab and Capecitabine (HER2CLIMB) in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer with Brain Metastases
SABCS 2021 Wrap-Up
Conference Correspondent
Tucatinib added to trastuzumab and capecitabine resulted in a substantial and permanent improvement of progression-free survival and overall survival for all patients with HER2-positive metastatic breast cancer with brain metastases, as confirmed by results from the HER2CLIMB study. Read More ›
Results from the I-SPY 2 Trial of Tucatinib plus Paclitaxel + Pertuzumab + Trastuzumab Followed by Doxorubicin/Cyclophosphamide in High-Risk HER2-Positive Stage II/III Breast Cancer
SABCS 2021 Wrap-Up
Conference Correspondent
Tucatinib-containing therapy resulted in a tumor volume reduction of >80%. Tucatinib was found to be highly effective when combined with paclitaxel plus trastuzumab plus pertuzumab. Read More ›
A Review of the Efficacy of Tyrosine Kinase Inhibitors in the Treatment of Patients with HER2-Positive Breast Cancer with or without Brain Metastases
SABCS 2021 Wrap-Up
Conference Correspondent
Tyrosine kinase inhibitor (TKI) treatments show equal overall survival and progression-free survival (PFS) benefits in patients with HER2-positive breast cancer with and without brain metastases. Read More ›
Intracranial Efficacy of Tucatinib, Palbociclib, and Letrozole in Patients with Hormone Receptor–Positive, HER2-Positive Breast Cancer with Brain Metastases
SABCS 2021 Wrap-Up
Conference Correspondent
The combination regimen of tucatinib, palbociclib, and letrozole in patients with hormone receptor–positive, HER2-positive breast cancer with brain metastases demonstrates an improved central nervous system progression-free survival in a small group of patients. Read More ›
Safety and Efficacy of a Tucatinib-Trastuzumab-Capecitabine Combination Treatment for Leptomeningeal Metastases in HER2-Positive Breast Cancer
SABCS 2021 Wrap-Up
Conference Correspondent
Tucatinib-trastuzumab-capecitabine combination therapy has been shown to double the overall survival in patients with HER2-positive breast cancer with leptomeningeal metastases. Read More ›